Johnson & Johnson announced today the first clinical data from an ongoing Phase 1b study for JNJ-90014496 (JNJ-4496), an investigational dual-targeting anti-CD19/CD20 bispecific autologous chimeric ...

The partnership will use Debiopharm's AbYlink conjugation tech in combination with Alkyon’s modular antibody platform.

Nanoplasmonic biosensors are revolutionizing virus detection, drug screening, and immune profiling, enhancing virology ...

MARTIGNY, Switzerland & LAUSANNE, Switzerland & SAN DIEGO, June 12, 2025--Debiopharm ( a privately-owned Swiss ...

Scientists have discovered a unique class of small antibodies that are strongly protective against a wide range of SARS ...

Recent innovations across the multiple ADC components, such as enhanced antibody-targeting to the tumors, better linker ...

A study in Chemistry A European Journal reveals that reduced MUC1 antigen density on gold nanoparticles still elicits potent ...

Objective To determine distinct patterns of patients with autoimmune diseases harbouring anti-Ku antibodies and their respective prognosis.Methods Anti-Ku-positive patients were retrieved through four ...

Research program combining Debiopharm's AbYlink conjugation technology with Alkyon's modular antibody platform and novel targeting approaches is set to drive next-generation targeted radiopharmaceutic ...

JNJ-79635322 shows favorable responses and manageable safety in BCMA/GPRC5D-naïve patients with relapsed/refractory multiple ...

Researchers design a nanovaccine that detects MRSA toxins, kills bacteria with heat, and captures antigens to train the ...